Oral Oncolytics Series: Leukemia, 2014 - 2024

  • Lowest Price Guaranteed From USD 1,899

  • Published
    May 2014

  • Pages
    139

  • View Count
    7006

  • Buy Now

Example Insights

  1. The market for oral targeted leukemia therapeutics was valued at USD 7,388 million in 2013; CML drugs currently dominate the market.
  2. US, with a 40.6% share, is currently the biggest market. According to the Leukemia & Lymphoma Society, there are an estimated 310,046 people living with, or in remission from, leukemia in the US
  3. Gleevec, the market leader, has been quite popular amongst patient population. However, its nearing patent expiry (2014, 2015, 2016 in Japan, the US and Europe respectively) will open the space for low cost generics
  4. There are several upcoming drugs, with a sizeable number in phase II and phase III clinical trials. Opportunities for drug developers exist in all forms of leukemia.
  5. AML has the most extensive pipeline; in addition to tyrosine kinases, hedgehog, JAK, PI3K inhibitors, drug developers are also exploring the use of epigenetic agents such as histone deacetylases (HDAC) and nuclear export inhibitors such as XPO1 inhibitor.
  6. Novartis is the most active company in this market, with two marketed drugs and another eight in clinical trials. Specifically, within AML (which currently has no marketed oral drug), Novartis’ Midostaurin is expected to have the first mover advantage.

Overview

Targeted therapeutics is fast emerging as the key focus area in biopharmaceutical industry. Oral targeted therapeutics has attracted many drug developers due to the ease of administration it offers to patients (especially pediatric and geriatric patients). In the case of leukemia, current marketed oral drugs include Gleevec, Tasigna, Sprycel, Bosulif, Imbruvica and Iclusig.

The high price of these drugs still remains a major constraint to the market growth. Further, as leukemia accounts for about 3% of all cancer cases per year, most of the companies are targeting other cancer indications offering a wider market prospective. The oral targeted drugs market is expected to be driven by new generation and new class of inhibitors. Several pharmaceutical companies, both big and small, are looking to capture a share of the leukemia market, where orally delivered drugs are well accepted.

Despite the impending patent expiry of some drugs (especially Gleevec), the market is set to rise after a likely dip in growth rate in the short-term. There are specific opportunities which remain to be tapped in the mid-long term; emerging drug therapies such as third generation tyrosine kinase inhibitors (TKIs), multi kinase inhibitors, FLT3 inhibitors, AKT kinase inhibitors and BTK inhibitors are likely to sustain the interest of drug makers.

 

Scope of the Report

The ‘Oral Oncolytics Series: Leukemia, 2014 - 2024’ report provides an extensive study of the market of oral targeted leukemia drugs, specifically focusing on currently commercialized drugs, those under development and the likely future market evolution. Targeted therapeutics have tremendous potential and the market is expected to grow steadily over the coming few years. The focus of our report is on drugs which target a specific marker / antigen on leukemia cells and are delivered through mouth. The report covers various aspects such as regulatory approvals, treatment cost, historical sales, product pipeline and industry research programs.

With the upcoming patent expiry of some well-known drugs, we have looked at how the market landscape is likely to change in the coming years. In fact, one of the key objectives of this report is to understand the current and future state of the oral targeted leukemia drugs. This is done by analyzing the following:

  • Marketed oral targeted leukemia drugs
  • Products in pipeline
  • Competing technologies and innovations
  • Growing target patient pool

The base year for the report is 2013. The report provides short-mid term and long term forecasts for the period 2014 - 2024. This forecast is supported by detailed research and analysis of drugs (both marketed / pipeline) which we believe will have a far-reaching impact on the market. Owing to the uncertainties associated with drug development and customer adoption trends, we have presented three different market scenarios for each of the drugs studied in this exercise:

  • Conservative Scenario: This represents our most pessimistic view of the success / adoption of each individual drug.
  • Base Scenario: This represents the most-likely success / adoption of respective drugs.
  • Aggressive Scenario: This is the bullish scenario wherein we have been aggressive in terms of the penetration rates of respective drugs and the likely market size.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of oral targeted leukemia market.

Chapter 3  provides a general introduction to leukemia. We have discussed, in detail, about types of leukemia, common signs and symptoms, its occurrence / prevalence and the current treatment regimes.

Chapter 4  provides an overview of the global leukemia therapeutics market, specifically the targeted therapeutics which includes small molecule inhibitors and monoclonal antibodies. The market has been analyzed on the basis of the type of leukemia, drug classes, and leading drugs in each segment.

Chapter 5  analyzes the current and future state of the worldwide market of oral targeted leukemia drugs. This chapter includes detailed profiles of all the marketed drugs and the drugs in phase III clinical trials. We have presented our estimates of the overall market value of oral targeted leukemia drugs till 2024.

Chapter 6  offers a region wise market analysis of the oral targeted leukemia drugs. This chapter covers the geographical availability and reimbursement policies of the oral targeted leukemia drugs. The major regional markets considered are the US, Europe and Japan.

Chapter 7  provides our analysis of the strengths, weaknesses, opportunities and threats impacting the oral targeted leukemia market, capturing key elements likely to influence future growth.  

Chapter 8  summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in earlier chapters.

Chapters 9 and 10  are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Leukemia
3.2. Types Of Leukemia
3.3. Common Signs And Symptoms
3.4. Incidence And Prevalence
3.5. Current Treatment Regimes
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Scope
4.3. Targeted Leukemia Therapeutics Market, 2013
4.3.1. Approved Targeted Leukemia Therapeutics, 2013
4.3.2. Within Leukemia, CML Drugs Dominate the Market
4.3.3. Four Leading Drugs Captured 98% of the Market in 2013
4.4. Oral Targeted Leukemia Therapeutics Market, 2013
4.5. Pipeline Analysis: By Specific Leukemia Sub-Types
4.5.1. Chronic Myeloid Leukemia (CML)
4.5.1.1. A Mature Market; Impending Threat of Patent Expiry
4.5.1.2. Development of Next Generation TKIs
4.5.1.3. Unravelling the Potential of Inhibitors Other Than Tyrosine Kinases
4.5.2. Chronic Lymphocytic Leukemia
4.5.2.1. Gazyva: Successor for Rituxan
4.5.2.2. Rich Pipeline Mainly Focusing on Relapsed / Refractory Population
4.5.3. Acute Myeloid Leukemia
4.5.3.1. A High Opportunity Area
4.5.3.2. Epigenetic Agents and Nuclear Export Inhibitors
4.5.4. Acute Lymphocytic / Lymphoblastic Leukemia (ALL)
4.5.4.1. Most Common Cancer in Children
4.5.4.2. Limited Molecules in Pipeline
4.6. Other Oral Targeted Drugs for Haematological Malignancies
 
5. ORAL TARGETED LEUKEMIA DRUGS: CURRENT MARKET AND FORECAST
5.1. Chapter Overview
5.1.1. Scope and Limitations
5.1.2. Market Forecast: Assumptions and Methodology
5.2. Overall Market Size and Forecast
5.2.1. Overall Oral Targeted Leukemia Drugs Market Forecast
 
5.3. Imatinib (Novartis Pharmaceuticals)
5.3.1. History of Development
5.3.2. Approval History
5.3.3. Mechanism of Action
5.3.4. Pricing and Reimbursement
5.3.5. Historical Sales
5.3.6. Launch of Generics in the Market
5.3.7. Withdrawal of Development in PAH
5.3.8. Gleevec Sales Forecast, Short-Mid Term (2014-2018)
5.3.9. Gleevec Sales Forecast, Long Term (2018-2024)
 
5.4. Nilotinib (Novartis Pharmaceuticals)
5.4.1. Approval History
5.4.2. Mechanism of Action
5.4.3. Tasigna and Gleevec: Novartis’ BCR/ABL Franchise
5.4.3.1. Moving Gleevec Patients to Tasigna before Patent Expiry
5.4.4. Treatment Cost
5.4.5. Historical Sales
5.4.6. Active Clinical Trials
5.4.7. Tasigna Sales Forecast, Short-Mid Term (2014-2018)
5.4.8. Tasigna Sales Forecast, Long Term (2018-2024)
 
5.5. Dasatinib (Bristol-Myers Squibb)
5.5.1. Orphan Drug Designations
5.5.2. Approval History
5.5.3. Mechanism of Action
5.5.4. Pricing and Reimbursement
5.5.5. Historical Sales
5.5.6. Active Clinical Trials
5.5.7. Patent Expiry and Generics
5.5.8. Sprycel Sales Forecast, Short-Mid Term (2014-2018)
5.5.9. Sprycel Sales Forecast, Long Term (2018-2024)
 
5.6. Bosutinib (Pfizer Inc.)
5.6.1. Approval History
5.6.2. Mechanism of Action
5.6.3. Pricing and Reimbursement
5.6.4. Historical Sales
5.6.5. Ongoing Clinical Trials
5.6.5.1. Partnership With Avillion for First-Line Treatment
5.6.6. Manufacturing
5.6.7. Bosutinib Sales Forecast, Short-Mid Term (2014-2018)
5.6.8. Bosutinib Sales Forecast, Long Term (2018-2024)
 
5.7. Ponatinib (ARIAD Pharmaceuticals, Inc.)
5.7.1. Approval and Launch History
5.7.2. Mechanism of Action
5.7.3. Setback and Re-launch in the US
5.7.4. Pricing and Reimbursement
5.7.5. Historical Sales
5.7.6. Ongoing Clinical Trials
5.7.7. Manufacturing
5.7.8. Iclusig Sales Forecast, Short-Mid Term (2014-2018)
5.7.9. Iclusig Sales Forecast, Long Term (2018-2024)
 
5.8. Ibrutinib (Pharmacyclics Inc./ Janssen Pharmaceuticals)
5.8.1. Historical Development
5.8.2. Breakthrough Therapy Designation
5.8.3. Mechanism of Action
5.8.4. Pricing and Reimbursement
5.8.5. Historical Sales
5.8.6. Market Expansion Strategies
5.8.7. Manufacturing of Ibrutinib
5.8.8. Ibrutinib Sales Forecast, Short-Mid Term (2014-2018)
5.8.9. Ibrutinib Sales Forecast, Long Term (2018-2024)
 
5.9. Idelalisib (Gilead Sciences, Inc.)
5.9.1. History of Development
5.9.2. Mechanism of Action
5.9.3. Another First-in-Class Inhibitor for CLL
5.9.4. Early Termination of Study GS-US-312-0116
5.9.5. Ongoing Clinical Trials
5.9.6. Idealisib Sales Forecast, Short-Mid Term (2014-2018)
5.9.7. Idealisib Sales Forecast, long term (2018-2024)
 
5.10. Midostaurin (Novartis Pharmaceuticals)
5.10.1. Orphan Drug Designations
5.10.2. Mechanism of Action
5.10.3. First Mover Advantage in the AML Market?
5.10.4. Screening for FLT3 Mutation
5.10.5. Active Clinical Trials
5.10.6. Midostaurin Sales Forecast, Short-Mid Term (2016-2018)
5.10.7. Midostaurin Sales Forecast, Long Term (2018-2024)
 
5.11. ABT-199 / GDC-0199 (Abbott / Roche)
5.11.1. Mechanism of Action
5.11.2. Screening for a Biomarker
5.11.3. A Temporary Clinical Hold
5.11.4. Active Clinical Trials
5.11.5. ABT-199 Sales Forecast, Long Term (2019-2024)
 
5.12. IPI – 145 (Infinity Pharmaceuticals / Millennium)
5.12.1. History of Development
5.12.2. Orphan Drug Designation
5.12.3. Mechanism of Action
5.12.4. Impressive Phase I Results Led to Phase III Trials
5.12.5. Active Clinical Trials
5.12.6. IPI-145 Sales Forecast, Long Term (2019-2024)
 
6. REGIONAL ANALYSIS OF ORAL TARGETED THERAPEUTICS MARKET
6.1. Overview
6.2. US is the Largest Market For Targeted Oral Leukemia Drugs
6.2.1. Epidemiology of Leukemia in the US
6.2.2. Availability and Reimbursement
6.3. Japan
6.3.1. Epidemiology of Leukemia in Japan
6.3.2. Availability and Reimbursement
6.4. Europe
6.4.1. Epidemiology of Leukemia in Europe
6.4.2. France
6.4.3. Germany
6.4.4. United Kingdom
 
7. SWOT ANALYSIS
7.1. Overview
7.2. Strengths
7.2.1. Ease of Administration
7.2.2. Positive Reimbursement Status in Major Developed Countries
7.3. Weaknesses
7.3.1. Small Patient Pool
7.3.2. High Annual Treatment Cost
7.4. Opportunities
7.4.1. Development of next generation TKIs
7.4.2. Limited Treatment Options for Pediatric Patients at Present
7.5. Threats
7.5.1. Development of Vaccines
7.5.2. Competition from Monoclonal Antibody Therapeutics
 
8. CONCLUSION
8.1. Leukemia: A Rare Disease in Adults but Most Common Cancer in Children
8.2. Six Drugs for Leukemia, None for AML Group of Patients
8.3. High Annual Treatment Cost: A Concern, Reimbursement Schemes to Relief
8.4. Despite Impending Patent Expiries, Market Set to Rise Further
8.5. Concluding Remarks
 
9. APPENDIX 1: List of Companies and Organizations
 
10. APPENDIX 2: Tabulated Data

List of Figuers

Figure 3.1 Leukemia: Incidence Rate in the US (2013)
Figure 3.2 Leukemia: Incidence Rate in the US by Age Group (2006 – 2010)
Figure 4.1 Targeted Leukemia Drugs Market, 2013 – Split by Indication (USD Million)
Figure 4.2 Targeted Leukemia Drugs Market, 2013 – Split by Leading Drugs (USD Million)
Figure 4.3 Oral Targeted Leukemia Drugs Market, 2013 (USD Million)
Figure 4.4 Targeted CML Therapeutics Market, 2013 (USD Million) – Split by Leading Drugs
Figure 4.5 Oral Targeted CML Drugs, 2014 – Split by Phase of Development
Figure 4.6 Targeted CLL Therapeutics Market, 2013 – Split by Leading Drugs (USD Million)
Figure 4.7 Oral Targeted CLL Drugs, 2014 – Split by Phase of Development
Figure 4.8 Oral Targeted AML Drugs, 2014 – Split by Phase of Development
Figure 4.9 Targeted ALL Therapeutics Market, 2013 – Split by Leading Drugs
Figure 4.10 Oral Targeted ALL Drugs, 2014 – Split by Phase of Development
Figure 5.1 Overall Oral Targeted Leukemia Drugs Market Forecast: Base Scenario (USD Million)
Figure 5.2 Gleevec/Glivec Sales, 2005-2013 (USD Million)
Figure 5.3 Gleevec/Glivec Sales by Region, 2013 (%)
Figure 5.4 Gleevec Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.5 Gleevec Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.6 Novartis BCR/ABL Franchise Sales, 2013 (USD Million)
Figure 5.7 Tasigna Sales, 2008-2013 (USD Million)
Figure 5.8 Tasigna Sales by Region, 2013 (%)
Figure 5.9 Tasigna Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.10 Tasigna Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.11 Sprycel Sales, 2006-2013 (USD Million)
Figure 5.12 Sprycel Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.13 Sprycel Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.14 Bosutinib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.15 Bosutinib Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.16 Iclusig Sales, 2013 (USD Million)
Figure 5.17 Iclusig Sales Distribution by Region, Q4 2013 (USD Million)
Figure 5.18 Iclusig Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.19 Iclusig Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.20 Ibrutinib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.21 Ibrutinib Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.22 Idealisib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.23 Idealisib Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.24 FLT3 Mutation in Acute Myeloid Leukemia Patients (%)
Figure 5.25 Midostaurin Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Figure 5.26 Midostaurin Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.27 ABT-199 Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 5.28 IPI-145 Sales Forecast, Long Term: Base Scenario (USD Million)
Figure 6.1 Oral Targeted Leukemia Drugs Market – Split by Regions, 2013 (%)
Figure 6.2 Prevalence of Leukemia in the US, 2013 (%)
Figure 6.3 Incidence of Types of Leukemia in the US, 2013 (%)
Figure 6.4 Oral Targeted Leukemia Drugs Market in the US, 2013 – Split by Drugs (USD Million)
Figure 6.5 Incidence of Leukemia in Japan, 2012
Figure 6.6 Leukemia Incidence: Major EU Countries, 2012
Figure 8.1 Oral Targeted Leukemia Drugs Market Forecast (USD Million): Comparative Scenarios

List of Tables

Table 4.1 List of Approved Targeted Drugs for ALL, 2013
Table 4.2 List of Approved Targeted Drugs for CLL, 2013
Table 4.3 List of Approved Targeted Drugs for CML, 2013
Table 4.4 Target Kinases for Approved Small Molecule Inhibitors
Table 4.5 Comparison of the Marketed Targeted Inhibitors for CML
Table 4.6 CML Pipeline: Oral Targeted Drugs, 2014
Table 4.7 Comparison of the Marketed Targeted Inhibitors for CLL
Table 4.8 Rituximab Biosimilars Under Development, 2014
Table 4.9 CLL Pipeline: Oral Targeted Drugs, 2014
Table 4.10 AML Pipeline: Oral Targeted Drugs, 2014
Table 4.11 Comparison of the Marketed Targeted Inhibitors for ALL
Table 4.12 ALL Pipeline: Oral Targeted Drugs, 2014
Table 4.13 Some More Oral Targeted Drugs for Leukemia, 2014
Table 5.1 Oral Targeted Leukemia Drugs (Phase III and Higher): Current Development Phase and Expected Launch Year
Table 5.2 Gleevec: Marketing Approvals
Table 5.3 Gleevec: Dosage Regime
Table 5.4 Tasigna: Orphan Drug Designation
Table 5.5 Tasigna: Marketing Approvals
Table 5.6 Tasigna: Treatment Duration and Cost
Table 5.7 Tasigna: Clinical Trials and Development Status
Table 5.8 Dasatinib: Orphan Drug Designation History
Table 5.9 Sprycel: Approval History
Table 5.10 Sprycel: Course and Treatment Cost
Table 5.11 Sprycel: Clinical Trials and Development Status
Table 5.12 Bosulif: Treatment Duration and Cost
Table 5.13 Bosulif: Clinical Trials and Development Status
Table 5.14 Ponatinib: Approval History
Table 5.15 Iclusig: Treatment Tenure
Table 5.16 Iclusig: Clinical Trials and Development Status
Table 5.17 Ibrutinib: Orphan Drug Designations
Table 5.18 Ibrutinib: Ongoing Clinical Trials
Table 5.19 Idelalisib: Clinical Trials and Development Status
Table 5.20 Midostaurin: Orphan Drug Designations
Table 5.21 Midostaurin: Clinical Trials and Development Status
Table 5.22 ABT-199: Clinical Trials and Development Status
Table 5.23 IPI - 145: Clinical Trials and Development Status
Table 6.1 Marketed Oral Targeted Drugs in Major Markets
Table 8.1 SWOT analysis of Oral Targeted Therapeutics for Leukemia
Table 10.1 Targeted Leukemia Drugs Market, 2013 – Split by Indication (USD Million)
Table 10.2 Targeted Leukemia Drugs Market, 2013 – Split by Leading Drugs (USD Million)
Table 10.3 Oral Targeted Leukemia Drugs Market, 2013 (USD Million)
Table 10.4 Targeted CML Therapeutics Market, 2013 (USD Million) – Split by Leading Drugs
Table 10.5 Targeted CLL Therapeutics Market, 2013 – Split by Leading Drugs (USD Million)
Table 10.6 Targeted ALL Therapeutics Market, 2013 – Split by Leading Drugs
Table 10.7 Overall Oral Targeted Leukemia Drugs Market Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.8 Overall Oral Targeted Leukemia Drugs Market Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.9 Overall Oral Targeted Leukemia Drugs Market Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.10 Overall Oral Targeted Leukemia Drugs Market Forecast, Long Term: Base Scenario (USD Million)
Table 10.11 Overall Oral Targeted Leukemia Drugs Market Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.12 Overall Oral Targeted Leukemia Drugs Market Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.13 Gleevec Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.14 Gleevec Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.15 Gleevec Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.16 Gleevec Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.17 Gleevec Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.18 Gleevec Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.19 Tasigna Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.20 Tasigna Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.21 Tasigna Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.22 Tasigna Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.23 Tasigna Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.24 Tasigna Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.25 Sprycel Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.26 Sprycel Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.27 Sprycel Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.28 Sprycel Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.29 Sprycel Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.30 Sprycel Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.31 Bosutinib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.32 Bosutinib Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.33 Bosutinib Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.34 Bosutinib Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.35 Bosutinib Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.36 Bosutinib Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.37 Iclusig Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.38 Iclusig Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.39 Iclusig Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.40 Iclusig Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.41 Iclusig Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.42 Iclusig Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.43 Ibrutinib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.44 Ibrutinib Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.45 Ibrutinib Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.46 Ibrutinib Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.47 Ibrutinib Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.48 Ibrutinib Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.49 Idealisib Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.50 Idealisib Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.51 Idealisib Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.52 Idealisib Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.53 Idealisib Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.54 Idealisib Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.55 Midostaurin Sales Forecast, Short-Mid Term: Base Scenario (USD Million)
Table 10.56 Midostaurin Sales Forecast, Short-Mid Term: Conservative Scenario (USD Million)
Table 10.57 Midostaurin Sales Forecast, Short-Mid Term: Optimistic Scenario (USD Million)
Table 10.58 Midostaurin Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.59 Midostaurin Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.60 Midostaurin Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.61 ABT-199 Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.62 ABT-199 Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.63 ABT-199 Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.64 IPI-145 Sales Forecast, Long Term: Base Scenario (USD Million)
Table 10.65 IPI-145 Sales Forecast, Long Term: Conservative Scenario (USD Million)
Table 10.66 IPI-145 Sales Forecast, Long Term: Optimistic Scenario (USD Million)
Table 10.67 Prevalence of Four Main Types of Leukemia in the US, 2013
Table 10.68 Incidence of Leukemia in the US, 2013 and 2014
Table 10.69 Oral Targeted Leukemia Drugs Market in the US, 2013 – Split by Drugs (USD Million)
Table 10.70 Incidence of Leukemia in Japan, 2012
Table 10.71 Leukemia Incidence: Major European Union Countries, 2012

Listed Companies

The following companies and organizations have been mentioned in the report:

  1. AbbVie
  2. Agios Pharmaceuticals
  3. Akinion Pharmaceuticals
  4. Ambit Biosciences Corporation
  5. Amgen
  6. Apotex
  7. ARIAD Pharmaceuticals
  8. Arog Pharmaceuticals
  9. Ascenta Therapeutics
  10. Ascerta Pharma
  11. Ash Stevens
  12. Astellas Pharma
  13. Asterias Biotherapeutics
  14. AstraZeneca
  15. Avillion Group
  16. Bayer
  17. BDR Pharma
  18. BioMarin Pharmaceutical
  19. Boehringer Ingelheim
  20. Bristol-Myers Squibb
  21. Calithera Biosciences
  22. Catalent
  23. Celltrion
  24. Chroma Therapeutics
  25. CytRx
  26. Dana-Farber Cancer Institute
  27. Esteve Quimica
  28. Exelixis
  29. Genentech
  30. Genzyme
  31. Gilead Sciences
  32. GlaxoSmithKline
  33. Haupt Pharma
  34. Il-Yang Pharm. Co.
  35. Incyte Corporation
  36. Infinity Pharmaceuticals
  37. Inovio
  38. Janssen
  39. Jiangsu HengRui Medicine Co.
  40. Karyopharm Therapeutics
  41. Kinex Pharmaceuticals
  42. Lonza
  43. Max Foundation
  44. MEI Pharma
  45. Merck
  46. Millenium Pharmaceuticals
  47. National Institute for Health and Care Excellence
  48. Novartis
  49. OncoEthix
  50. Onconova Therapeutics, Inc.
  51. Ono Pharmaceutical Co. Ltd
  52. Otsuka Pharmaceutical
  53. Pfizer
  54. Pharmacyclics
  55. Piramal Enterprises Limited
  56. Plexxikon
  57. Portola Pharmaceuticals
  58. Roche
  59. Samsung Biologics
  60. Sandoz
  61. Sanofi
  62. Specialised Therapeutics Australia Pty Ltd (STA)
  63. Tesaro
  64. Teva Pharmaceuticals
  65. TG Therapeutics
  66. Tragara Pharmaceuticals, Inc.
  67. University of Southampton
  68. Wyeth

PRICING DETAILS

USD 1,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © 2023 Roots Analysis. All Rights Reserved.